Next big bet: Experts bullish on Bharat Biotech's upcoming nasal vaccine

Bharat Biotech is currently working on two intra-nasal vaccines

Bharat Biotech is bullish on its upcoming nasal vaccine, which in under trial in the US. Experts say the vaccine, if successful, could play a major role in stopping transmission of the virus, and lead to eradication of the disease from the globe.
 

The firm recently received restricted emergency use approval from India’s drug regulator for its intra-muscular vaccine Covaxin.

Bharat Biotech is working on two intra-nasal vaccines, one with US-based vaccine maker FluGen and scientists from the University of Wisconsin Madison, and the other with the University of Washington School of Medicine.
 

Meanwhile, Hindustan Syringes and Medical Devices (HMD)